Elsevier

Human Pathology

Volume 37, Issue 8, August 2006, Pages 1000-1008
Human Pathology

Original contribution
Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy

https://doi.org/10.1016/j.humpath.2006.03.014Get rights and content

Summary

L1 cell adhesion molecule (CD171) represents a strongly unfavorable prognostic biomarker for ovarian and endometrial carcinomas. Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10. In normal tissues, L1 was expressed in the collecting tubules of adult tissues and pediatric kidney and in peripheral nerve bundles. In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas. Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system. L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas. Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo. Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.

Introduction

Despite considerable diagnostic and therapeutic achievements in the treatment of human carcinomas, there is still urgent need for better molecular tumor markers. Carcinomas often reexpress molecules involved in tissue morphogenesis and fetal development that are silenced in adult tissues. Such molecules could represent novel markers with the potential to be tumor targets for antibody-based therapy and serve for improved diagnostics.

The L1 adhesion molecule is a 200- to 220-kd type I membrane glycoprotein of the immunoglobulin super family, consisting of 6 immunoglobulin-like domains and 5 fibronectin type III repeats followed by a transmembrane region and a highly conserved cytoplasmic tail [1]. In neuronal cells, L1 is involved in morphogenic events, such as neuron-neuron adhesion, neurite fasciculation, synaptogenesis, neurite outgrowth on Schwann cells, and neuronal cell migration (for review, see Refs. [2], [3]). L1 is also involved in the branching of renal tubules during kidney development [4]. Low levels of L1 are expressed in hematopoietic cells [5], [6].

Several studies have previously investigated L1 expression in tumors using established cell lines, and fresh frozen or fixed paraffin-embedded tissues. L1 was found in lung cancer cell lines [7], gliomas [8], melanomas [9], [10], renal carcinoma [11], [12], ovarian and endometrial carcinomas [13], and colon carcinoma [14]. In melanoma [9], [10] and in ovarian/endometrial carcinoma [13], the presence of L1 was found to be associated with poor patient prognosis. Similar results have recently been shown for gastrointestinal (GI) stromal tumors [14]. In colon carcinoma, overexpression of L1 has been linked to aberrant β-catenin/T-cell factor signaling [15].

Our recent studies have shown that L1 might be a valuable new target for tumor therapy. We found that L1 monoclonal antibodies (mAbs) could block the proliferation of tumor cells in vitro and in vivo [16]. Anti-L1 mAb administration was capable of reducing tumor load and ascites formation from SKOV3 cells in NOD/Scid mice [16]. Before applying for clinical testing, a detailed analysis of L1 expression in tumors and normal tissues is urgently needed. Such an analysis was hampered by the lack of appropriate antibodies working in paraffin-embedded tissues. The availability of mAb L1-11A and the newly produced L1-specific mAb L1-14.10 has solved these technical problems. The present study provides a comprehensive analysis of L1 expression in normal adult and in a broad range of benign and malignant tumors.

Section snippets

Cells and antibodies

The breast cancer cell lines MCF7 and MDA-MB 435S were obtained from the tumor bank of DKFZ (Heidelberg, Germany). The human renal carcinoma cell lines Caki-1 and Foehn were derived from Ilse Novak-Hofer (PSI, Villingen, Switzerland). The ovarian carcinoma cell lines OVM and SKOV3 as well as CHO cells stably transfected with human L1 were described before [13]. All cells were cultivated in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum at 37°C, 5% CO2, and 100%

Characterization of L1-specific mAbs

Using immunization with a recombinant L1-Fc fusion protein, we generated the novel L1 mAb L1-14.10. The mAb was specific for L1 as revealed by fluorescent staining (Fig. 1A) and Western blot analysis (Fig. 1B). Monoclonal antibody L1-14.10 was superior to the established mAb L1-11A in immunohistochemistry on paraffin sections, resulting in a more intense staining (Fig. 1C). The staining pattern of both mAbs was otherwise identical. Data presented in this study were obtained with both antibodies.

Discussion

L1 is a novel marker protein for ovarian and endometrial carcinomas with the potential to serve as a therapeutic target [16]. In the present study, we carried out a survey in human carcinomas and adult normal tissue to broaden our knowledge on the expression of L1. Our results show that L1 expression in tumors is restricted and not ubiquitous. Whereas expression in melanomas can be expected because of the neuroendocrine origin of these tumors, the expression in gynecological tumors is possibly

Acknowledgements

We thank Ludmila Braginsky for her skillful technical assistance, Brigitte Engelhardt for competent help with the artwork, and Dr Michael Sanderson for helpful comments on the manuscript.

References (29)

  • O. Ebeling et al.

    L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin

    Eur J Immunol

    (1996)
  • J.D. Pancook et al.

    Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin

    J Immunol

    (1997)
  • M. Katayama et al.

    Expression of neural cell adhesion molecule L1 in human lung cancer cell lines

    Cell Struct Funct

    (1997)
  • V. Senner et al.

    L1 expressed by glioma cells promotes adhesion but not migration

    Glia

    (2002)
  • Cited by (73)

    • A novel method for measuring cellular antibody uptake using imaging flow cytometry reveals distinct uptake rates for two different monoclonal antibodies targeting L1

      2015, Journal of Immunological Methods
      Citation Excerpt :

      Many studies in the past decade associated L1 expression with a variety of tumor-promoting functions such as cell motility and invasion, thus contributing to cancer progression and metastasis (Meier et al., 2006; Sebens Müerköster et al., 2007; Zeimet et al., 2013). Consequently, overexpression of L1 in different human carcinomas has been linked to poor prognosis, more aggressive phenotype and advanced stages (Fogel et al., 2003a; Huszar et al., 2006). Taken together, L1 is an attractive target for antibody-based specific cancer therapy (Novak-Hofer et al., 2008).

    View all citing articles on Scopus

    This work was supported by grant 10-2024-Al4 (P. A.) from the Deutsche Krebshilfe and a guest scientist stipend from DKFZ (M. F.).

    View full text